Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

03 June 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of EGFR/HER3 Dual Payload Bispecific ADC JSKN021 JSKN021 is the company’s sixth ADC candidate entering clinical development, as well as its first dual payload ADC to advance into clinical trials
02 June 2026

2026 ASCO | Alphamab Oncology Presented Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer JSKN016 demonstrated very promising efficacy and superior safety profile in late line HER2-negative BC patients
01 June 2026

2026 ASCO | Alphamab Oncology Announces Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Presented at LBA Oral Presentation Session This study is the first Phase III clinical trial worldwide to directly demonstrate that a bispecific antibody has superior efficacy to the combination of two monospecific antibodies targeting the same...
29 May 2026

First HER2 Bispecific Antibody for Second-Line Gastric Cancer in China! Alphamab Oncology Announces Anbenitamab (KN026) Obtained Marketing Approval from NMPA, Opening a New Era in Advanced Gastric Cancer Treatment As the first domestically developed HER2 bispecific antibody approved for marketing in China, it is expected to reshape the treatment landscape
22 May 2026

Patient Enrollment Completed in a Phase III Neoadjuvant/Adjuvant Study in Non‑Small Cell Lung Cancer of Envafolimab This milestone marks significant progress for Envafolimab in the perioperative treatment of early‑stage lung cancer and is expected to provide a more convenient and safer subcutaneous immunotherapy o...
20 May 2026

International Clinical Trials Day | A Love Letter to Life, A Tribute to Innovation Putting patients first and prioritizing clinical value is our everlasting original aspiration
13 May 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer this study is expected to bring an efficient, safe, and convenient first‑line treatment option to patients with advanced cervical cancer
12 May 2026

Alphamab Oncology Announces the First Patient Dosed in Australia Phase I Clinical Study of Subcutaneous TROP2/HER3 Bispecific ADC JSKN016 JSKN016 is designed to address unmet clinical needs, reshaping the ADC treatment experience through formulation innovation
08 May 2026

World Ovarian Cancer Day | Shine Bright, Be the Leading Lady of Life Every medical innovation and clinical advancement breaks the shackles of disease, embodying our commitment to safeguarding patients' love, dignity and hope
30 April 2026

Alphamab Oncology Announces IND Application for TROP2/HER3 Bispecific ADC JSKN016SC Officially Accepted by CDE This application is being reviewed under the "30‑day review channel" for innovative drug clinical trials